Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 14Neoplasm Metastasis 5Rectal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Stomach Neoplasms 2Gallbladder Neoplasms 2Colonic Neoplasms 2Pancreatic Neoplasms 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gastric Adenocarcinoma 1Digestive System Diseases 1Cholangiocarcinoma 1Carcinoma 1Bile Duct Neoplasms 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumors 1Adenocarcinoma 1

Interventions

tislelizumab 4talazoparib 4pembrolizumab 4Docetaxel 4Nivolumab 3PM 01183 2MLN 8237 2Itraconazole 2Fluorouracil 2Cisplatin 2Carboplatin 2zimberelimab 1utomilumab 1urelumab 1ulixertinib 1trifluridine tipiracil drug combination 1sitravatinib 1sapanisertib 1pexidartinib 1pevonedistat 1peposertib 1niraparib 1mogamulizumab 1lenvatinib 1ixabepilone 1eribulin 1durvalumab 1dalotuzumab 1avelumab 1ascrinvacumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Solid Tumors × trifluridine tipiracil drug combination × Clear all
NCT04393298 2025-05-29

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

UCB Pharma

Phase 1/2 Completed
93 enrolled 28 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡